Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review

Systemic lupus erythematosus (SLE) is a chronic pathology characterized by a bimodal mortality pattern attributed to clinical disease activity and cardiovascular disease (CVD). A complex interaction between traditional CVD risk factors such as obesity, dyslipidemia, smoking, insulin resistance, metabolic syndrome, and hypertension, as well as the presence of non-traditional CVD risk factors such as hyperhomocysteinemia, pro-inflammatory cytokines, and C-reactive protein levels, has been suggested as a cause of the high prevalence of CVD in SLE patients. On the other hand, environmental factors, such as nutritional status, could influence the disease’s prognosis; several nutrients have immunomodulators, antioxidants, and anti-cardiometabolic risk properties which could reduce SLE severity and organ damage by decreasing the development of traditional and non-traditional CVD risk factors. Therefore, this critical literature review discusses the therapeutic potential of nutritional approaches that could modulate the development of the main comorbidities related to CVD risk in SLE patients.

[1]  A. Kalea,et al.  Diet and Systemic Lupus Erythematosus (SLE): From Supplementation to Intervention , 2022, International journal of environmental research and public health.

[2]  Minjian Kong,et al.  Systemic Lupus Erythematosus and Cardiovascular Disease: A Mendelian Randomization Study , 2022, Frontiers in Immunology.

[3]  B. Szponar,et al.  Serum levels of n-3 and n-6 polyunsaturated fatty acids in patients with systemic lupus erythematosus and their association with disease activity: a pilot study , 2021, Scandinavian journal of rheumatology.

[4]  N. Žarković,et al.  Oxidative Stress and Lipid Mediators Modulate Immune Cell Functions in Autoimmune Diseases , 2021, International journal of molecular sciences.

[5]  J. Muñóz-Valle,et al.  Association of cardiometabolic risk status with clinical activity and damage in systemic lupus erythematosus patients: A cross-sectional study. , 2020, Clinical immunology.

[6]  S. Rahman,et al.  LOX-1: A potential driver of cardiovascular risk in SLE patients , 2020, PloS one.

[7]  D. Ye,et al.  Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis , 2020, Clinical Rheumatology.

[8]  D. Nikolopoulos,et al.  Cardiovascular Disease in Systemic Lupus Erythematosus: recent data on epidemiology, risk factors and prevention. , 2019, Current vascular pharmacology.

[9]  M. Garaulet,et al.  Relationship of Excess Weight with Clinical Activity and Dietary Intake Deficiencies in Systemic Lupus Erythematosus Patients , 2019, Nutrients.

[10]  M. Bäck,et al.  The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification , 2019, Seminars in Immunopathology.

[11]  M. Hosseinzadeh‐Attar,et al.  Effects of Selenium Supplementation on Asymmetric Dimethylarginine and Cardiometabolic Risk Factors in Patients with Polycystic Ovary Syndrome , 2019, Biological Trace Element Research.

[12]  W. Tissing,et al.  Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia , 2019, PloS one.

[13]  C. Ruiz,et al.  Vitamin D and autoimmune diseases. , 2019, Life sciences.

[14]  A. Ruiz-Arguelles,et al.  Systemic lupus erythematosus and hypertension. , 2019, Autoimmunity reviews.

[15]  Tianfu Wu,et al.  Elevated oxidized lipids, anti-lipid autoantibodies and oxidized lipid immune complexes in active SLE. , 2019, Clinical immunology.

[16]  R. Manno,et al.  Hyperhomocysteinemia and Lupus Nephritis , 2019, Cureus.

[17]  C. Mok Metabolic syndrome and systemic lupus erythematosus: the connection , 2019, Expert review of clinical immunology.

[18]  A. La Cava The Influence of Diet and Obesity on Gene Expression in SLE , 2019, Genes.

[19]  D. Bonaduce,et al.  Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients , 2019, International journal of molecular sciences.

[20]  Dahai Yu,et al.  Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients , 2019, Medicine.

[21]  N. Olsen,et al.  Selenium supplementation suppresses immunological and serological features of lupus in B6.Sle1b mice , 2019, Autoimmunity.

[22]  L. Trupin,et al.  Racial/Ethnic Differences in Prevalence of and Time to Onset of SLE Manifestations: The California Lupus Surveillance Project (CLSP). , 2019, Arthritis care & research.

[23]  T. Desai,et al.  Pro-resolving lipid mediators in vascular disease. , 2018, The Journal of clinical investigation.

[24]  H. Moutsopoulos,et al.  Contribution of MTHFR gene variants in lupus related subclinical atherosclerosis. , 2018, Clinical immunology.

[25]  Yeonseok Chung,et al.  Dyslipidemia promotes germinal center reactions via IL-27 , 2018, BMB Reports.

[26]  Ahmed Rebai,et al.  Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients , 2018, Inflammation Research.

[27]  G. Lima,et al.  C-reactive protein (CRP) polymorphisms and haplotypes are associated with SLE susceptibility and activity but not with serum CRP levels in Mexican population , 2018, Clinical Rheumatology.

[28]  K. Elmusharaf,et al.  Effect of Gum Arabic (Acacia Senegal) supplementation on visceral adiposity index (VAI) and blood pressure in patients with type 2 diabetes mellitus as indicators of cardiovascular disease (CVD): a randomized and placebo-controlled clinical trial , 2018, Lipids in Health and Disease.

[29]  A. Afeltra,et al.  Physical activity and sedentary behavior in patients with Systemic Lupus Erythematosus , 2018, PloS one.

[30]  A. Mangoni,et al.  Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus , 2018, Mediators of inflammation.

[31]  Y. Shoenfeld,et al.  Antiphospholipid syndrome , 2018, Nature Reviews Disease Primers.

[32]  J. Rosa,et al.  Homocysteine, folate, hs-C-reactive protein, tumor necrosis factor alpha and inflammatory proteins: are these biomarkers related to nutritional status and cardiovascular risk in childhood-onset systemic lupus erythematosus? , 2018, Pediatric Rheumatology.

[33]  W. Ling,et al.  Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals. , 2017, Journal of clinical lipidology.

[34]  S. N. Murthy,et al.  The metabolism and significance of homocysteine in nutrition and health , 2017, Nutrition & Metabolism.

[35]  Y. Shoenfeld,et al.  Vitamin D and Autoimmune Diseases , 2017 .

[36]  F. Wilson,et al.  Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. , 2017, Seminars in arthritis and rheumatism.

[37]  C. Mavragani,et al.  Cardiovascular disease in systemic lupus erythematosus: A comprehensive update. , 2017, Journal of autoimmunity.

[38]  Anisur Rahman,et al.  Atherosclerosis in systemic lupus erythematosus. , 2017, Best practice & research. Clinical rheumatology.

[39]  R. Hegele,et al.  Functional foods and dietary supplements for the management of dyslipidaemia , 2017, Nature Reviews Endocrinology.

[40]  R. Pandey,et al.  Effects of 3 g of soluble fiber from oats on lipid levels of Asian Indians - a randomized controlled, parallel arm study , 2017, Lipids in Health and Disease.

[41]  M. Sánchez-Hidalgo,et al.  An update on diet and nutritional factors in systemic lupus erythematosus management , 2017, Nutrition Research Reviews.

[42]  P. Szodoray,et al.  Dyslipidemia in systemic lupus erythematosus , 2017, Immunologic Research.

[43]  E. Lubberts,et al.  Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential , 2017, Front. Immunol..

[44]  M. Mansuri,et al.  Association of Neuropeptide-Y (NPY) and Interleukin-1beta (IL1B), Genotype-Phenotype Correlation and Plasma Lipids with Type-II Diabetes , 2016, PloS one.

[45]  C. Torp-Pedersen,et al.  Incidence of Systemic Lupus Erythematosus and Lupus Nephritis in Denmark: A Nationwide Cohort Study , 2016, The Journal of Rheumatology.

[46]  D. Ray,et al.  Vitamin D improves endothelial dysfunction and restores myeloid angiogenic cell function via reduced CXCL-10 expression in systemic lupus erythematosus , 2016, Scientific Reports.

[47]  Caroline Gordon,et al.  The frequency and outcome of lupus nephritis: results from an international inception cohort study. , 2016, Rheumatology.

[48]  M. Wigren,et al.  Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention , 2015, Journal of internal medicine.

[49]  F. Dall’ara,et al.  Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D , 2015, Lupus.

[50]  B. Jortner,et al.  Paradoxical Effects of All-Trans-Retinoic Acid on Lupus-Like Disease in the MRL/lpr Mouse Model , 2015, PloS one.

[51]  R. Cecchini,et al.  Fish Oil N-3 Fatty Acids Increase Adiponectin and Decrease Leptin Levels in Patients with Systemic Lupus Erythematosus , 2015, Marine drugs.

[52]  J. Asara,et al.  Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin , 2015, Metabolomics.

[53]  M. Mahmoudi,et al.  Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus , 2015, Immunopharmacology and immunotoxicology.

[54]  Hong Zhou,et al.  Involvement of TLR4 in oxidized LDL/β2GPI/anti-β2GPI-induced transformation of macrophages to foam cells. , 2014, Journal of atherosclerosis and thrombosis.

[55]  Y. Shoenfeld,et al.  Obesity in autoimmune diseases: not a passive bystander. , 2014, Autoimmunity reviews.

[56]  A. Saboor-Yaraghi,et al.  Vitamin A Supplementation Reduces IL‐17 and RORc Gene Expression in Atherosclerotic Patients , 2014, Scandinavian journal of immunology.

[57]  M. Kivimaki,et al.  Combined effect of physical activity and leisure time sitting on long-term risk of incident obesity and metabolic risk factor clustering , 2014, Diabetologia.

[58]  N. Costedoat-Chalumeau,et al.  Hydroxychloroquine: a multifaceted treatment in lupus. , 2014, Presse medicale.

[59]  D. Bikle,et al.  Vitamin D metabolism, mechanism of action, and clinical applications. , 2014, Chemistry & biology.

[60]  A. Sawalha,et al.  Diet influences expression of autoimmune-associated genes and disease severity by epigenetic mechanisms in a transgenic mouse model of lupus. , 2013, Arthritis and rheumatism.

[61]  Simone Appenzeller,et al.  Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus , 2013, Current cardiology reviews.

[62]  M. Correia,et al.  Excess weight and associated risk factors in patients with systemic lupus erythematosus , 2013, Rheumatology International.

[63]  M. Correia,et al.  Nutritional status and food intake in patients with systemic lupus erythematosus. , 2012, Nutrition.

[64]  D. Greco,et al.  Leptin-Induced mTOR Activation Defines a Specific Molecular and Transcriptional Signature Controlling CD4+ Effector T Cell Responses , 2012, The Journal of Immunology.

[65]  Stephen V Faraone,et al.  N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[66]  B. Illades-Aguiar,et al.  Common variants in the CRP gene are associated with serum C-reactive protein levels and body mass index in healthy individuals in Mexico. , 2012, Genetics and molecular research : GMR.

[67]  S. Azar,et al.  Effect of lysine, vitamin B(6), and carnitine supplementation on the lipid profile of male patients with hypertriglyceridemia: a 12-week, open-label, randomized, placebo-controlled trial. , 2012, Clinical therapeutics.

[68]  Shigeru Inoue,et al.  The pandemic of physical inactivity: global action for public health , 2012, The Lancet.

[69]  T. Gheita,et al.  The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis , 2012, International journal of rheumatic diseases.

[70]  W. Callaghan,et al.  Hypertension in Women of Reproductive Age in the United States: NHANES 1999-2008 , 2012, PloS one.

[71]  E. Bonfá,et al.  Diet and nutritional aspects in systemic lupus erythematosus. , 2012, Revista brasileira de reumatologia.

[72]  J. Manson,et al.  The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. , 2012, Contemporary clinical trials.

[73]  J. Kuk,et al.  Relation of physical activity to cardiovascular disease mortality and the influence of cardiometabolic risk factors. , 2011, The American journal of cardiology.

[74]  B. Hahn,et al.  Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention , 2011, Expert review of clinical immunology.

[75]  M. Kaplan,et al.  The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus , 2011, Arthritis research & therapy.

[76]  P. Menheere,et al.  Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis , 2010, PloS one.

[77]  J. Coombes,et al.  Omega-3 polyunsaturated fatty acids in the treatment of kidney disease. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[78]  S. Kardia,et al.  Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population , 2010, BMC public health.

[79]  B. Chandrasekar,et al.  Docosahexaenoic Acid-Enriched Fish Oil Attenuates Kidney Disease and Prolongs Median and Maximal Life Span of Autoimmune Lupus-Prone Mice , 2010, The Journal of Immunology.

[80]  J. Pestka n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis. , 2010, Prostaglandins, leukotrienes, and essential fatty acids.

[81]  M. Ward,et al.  Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. , 2010, Clinical and experimental rheumatology.

[82]  Z. Fayad,et al.  Associations between plasma C-reactive protein levels and the severities of coronary and aortic atherosclerosis. , 2010, Journal of atherosclerosis and thrombosis.

[83]  A. Kuryliszyn-Moskal,et al.  Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients , 2010, Clinical Rheumatology.

[84]  Stampfer,et al.  Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. , 2009, Arthritis and rheumatism.

[85]  D. Panagiotakos,et al.  Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. , 2008, Arthritis and rheumatism.

[86]  P. Raggi,et al.  Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[87]  J. Manson,et al.  Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. , 2008, JAMA.

[88]  S. Appenzeller,et al.  Cardiovascular Disease in Systemic Lupus Erythematosus: The Role of Traditional and Lupus Related Risk Factors , 2008, Current cardiology reviews.

[89]  E. McCarthy,et al.  Obesity and C‐reactive Protein Levels Among White, Black, and Hispanic US Adults , 2008, Obesity.

[90]  M. Abrahamowicz,et al.  Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? , 2008, Arthritis and rheumatism.

[91]  I. Bruce,et al.  Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. , 2008, Arthritis and rheumatism.

[92]  G. McVeigh,et al.  A randomised interventional trial of ω-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.

[93]  P. Jacques,et al.  In vitamin B12 deficiency, higher serum folate is associated with increased total homocysteine and methylmalonic acid concentrations , 2007, Proceedings of the National Academy of Sciences.

[94]  H. Stangl,et al.  Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaireds⃞ Published, JLR Papers in Press, July 9, 2007. , 2007, Journal of Lipid Research.

[95]  P. Low,et al.  Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. , 2007, Molecular pharmaceutics.

[96]  C. Sandborg,et al.  Review: Management of dyslipidemia in children and adolescents with systemic lupus erythematosus , 2007 .

[97]  T. Matsuo,et al.  Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[98]  P. Raggi,et al.  High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors , 2006, Annals of the rheumatic diseases.

[99]  H. Otani,et al.  The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: a preliminary study , 2007, Clinical Rheumatology.

[100]  C. Stein,et al.  Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[101]  V. Lee,et al.  Effects of vitamins C and E on oxidative stress markers and endothelial function in patients with systemic lupus erythematosus: a double blind, placebo controlled pilot study. , 2005, The Journal of rheumatology.

[102]  Victoria Moreno-Manzano,et al.  Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. , 2004, Kidney international.

[103]  J. Strain,et al.  The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. , 2004, The Journal of rheumatology.

[104]  G. Fernandes,et al.  Food Restriction and Fish Oil Suppress Atherogenic Risk Factors in Lupus-Prone (NZB × NZW) F1 Mice , 2004, Journal of Clinical Immunology.

[105]  A. Leibovitz,et al.  Anemia, serum vitamin B12, and folic acid in patients with rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus , 2004, Rheumatology International.

[106]  L. Klareskog,et al.  Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[107]  C. Gordon,et al.  Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia. , 2003, Rheumatology.

[108]  Yuji Nozaki,et al.  Retinoic Acid Reduces Autoimmune Renal Injury and Increases Survival in NZB/W F1 Mice , 2003, The Journal of Immunology.

[109]  Y. Minami,et al.  Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients. , 2003, The Journal of rheumatology.

[110]  B. Meyer,et al.  Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids , 2003, Lipids.

[111]  Peter Eck,et al.  Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention , 2003, Journal of the American College of Nutrition.

[112]  G. Jahreis,et al.  Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol , 2002, European Journal of Clinical Nutrition.

[113]  W. Hörl,et al.  Influence of mycophenolic acid and tacrolimus on homocysteine metabolism. , 2002, Kidney international.

[114]  M. Petri Diet and systemic lupus erythematosus: from mouse and monkey to woman? , 2001, Lupus.

[115]  D. Brady,et al.  Natural medicine and nutritional therapy as an alternative treatment in systemic lupus erythematosus. , 2001, Alternative medicine review : a journal of clinical therapeutic.

[116]  F. Formiga,et al.  Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients , 2001, Lupus.

[117]  A. Leiba,et al.  Diet and lupus , 2001, Lupus.

[118]  A. Brown Lupus erythematosus and nutrition: a review of the literature. , 2000, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[119]  L. Adorini,et al.  1α,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation , 2000, The Journal of Immunology.

[120]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[121]  D. Troyer,et al.  Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor β mRNA and Protein Expression , 1995 .

[122]  B. Weimann,et al.  Effects of Antioxidant Vitamins C, E, and β‐Carotene on Immune Functions in MRL/Ipr Mice and Rats , 1992 .

[123]  J. Lemire,et al.  1,25-Dihydroxyvitamin D3 Attenuates of Expression of Experimental Murine Lupus of MRL/1 Mice , 1992 .